Editorial Board member, Eleni Andreopoulou, spoke to us at the 2019 ASCO annual meeting about the advances made in immunotherapy for the treatment of breast cancer.
In Part 2 Eleni discusses promising combined immunotherapeutic regimens and how we can identify patients that could benefit from this type of therapy.
1. What combined immunotherapeutic regimens appear to be most promising in breast cancer? (0:04)
2. How can we select patients who are most likely to respond to combined immunotherapy approaches? (3:57)
Speaker disclosure: Eleni Andreopoulou has nothing to disclosure in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Breast Cancer
Matthew Goetz, ESMO 2022: MONARCH 3 trial – Interim overall survival results of abemaciclib + NSAI in patients with HR+, HER2- advanced breast cancer
The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 […]
Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer
Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, […]
Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!